Is there cost reduction potential for extended half-life cephalosporins?
Two new second-generation cephalosporin derivatives with extended half-lives, ceforanide and cefonicid, have recently entered the U.S. marketplace. Because longer dosing intervals require fewer daily doses, potential exists for overall cost reduction if pharmacy and nursing time can be effectively saved. Reduction in personnel costs, however, must be sufficient for these more expensive products to be truly cost effective. We studied the impact of substituting these newer agents for older, less expensive products with formulary status at our 200-bed community hospital. Results show that no nursing expenses could be recovered, and there is little chance of consistently reducing pharmacy compounding expenses. Within the constraints of these studies, particularly physician prescribing habits, the GRASP (Grace Reynolds Application and Study of PETO) system of determining nurse staffing, and our drug acquisition costs, we find that the newer extended half-life products have very limited usefulness and may only increase the cost of antibiotic utilization.
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000627:therapeutic use; D002511:Cephalosporins / Q000378:metabolism / Q000627:therapeutic use*; D003120:Colorado; D003365:Costs and Cost Analysis; D004363:Drug Utilization; D006207:Half-Life; D006744:Hospital Bed Capacity, 100 to 299; D006801:Humans; D010607:Pharmacy Service, Hospital / Q000191:economics*; D013530:Surgical Wound Infection / Q000517:prevention & control*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins